Metformin treatment prevents experimental metabolic syndrome-induced femoral bone marrow adiposity in rats.

Metabolic syndrome induced by a fructose-rich diet increases femoral medullary adiposity and, in part, the adipogenic predisposition of BMPC. In turn, this can be totally or partially prevented by oral co-treatment with MET.